Dr. David Goodman, Chief Executive Officer, Pharmascience Inc., receives CHLA Partnership Excellence Award in Life Sciences
MONTREAL, Feb. 5, 2015 /CNW Telbec/ - Pharmascience Inc., a top 10 Canadian pharmaceutical company with leading generics and fast-growing branded divisions, was last night awarded the Partnership Excellence Award in Life Sciences at the 2015 Canadian Healthcare Licensing Association (CHLA) Winter Meeting held in Mont-Tremblant, Quebec.
Partnerships form the core of Pharmascience's identity, and with double-digit growth over the past five years, the company's generic and innovative product agreements make it one of the top dealmakers in the Canadian pharmaceutical industry. As the largest pharmaceutical employer in Quebec, this award recognizes not only the value of Pharmascience's work to the lifesciences community, but also its contribution to Canadian academic research.
"It is an honour to be recognized by the industry and by our peers for the strategic partnerships that we have established over the years," said Dr. David Goodman, Chief Executive Officer of Pharmascience at the First Annual Trifermed Canada Awards Dinner held in conjunction with the 2015 CHLA Winter Meeting. "This award acknowledges our collaborative approach that aims to provide patients with access to affordable and quality medicine that is safe and efficient as well as innovative new treatments addressing patients' needs. We are very proud of the partnerships that we have created over the years and we look forward to developing new opportunities in the future."
The company has recently completed multiple generic and innovative product partnerships, including the ARTERIA project with the Montreal Heart Institute, a multi-faceted collaboration with Université de Montréal, and an alliance with Gilead Sciences to offer a new treatment option for patients with hepatitis C.
"The quality of partnerships that Pharmascience has secured in both academia and industry are a testament to their innovative business model and work" said Claude Larose, President, CHLA. With multiple direct entrepreneurial investments in companies in Canada and abroad in the last year, Pharmascience aims to build its pipeline and geographic reach, with investment to expand its footprint in the injectable business made in support of its plan to expand into both the United States and emerging markets.
About the Canadian Healthcare Licensing Association (CHLA)
The Canadian Healthcare Licensing Association (CHLA) is a non-profit organization formed in 1993. With a membership of 90 companies and 125 individual members, the CHLA's mission is to stimulate the building of relationships and the development of strategic alliances among companies and institutions engaged in the provision of healthcare products to Canadians. To learn more visit: www.chlassoc.com.
About Trifermed Canada
Trifermed is a life sciences partnering company specializing in project management from business modeling to final agreement. Trifermed has successfully managed over 130 deals between life sciences stakeholders around the world and bases its development on three strategic pillars: partnering services, non-for-profit academy activities and expertise and the alliance, which is a network of excellence consisting of service providers and specialists across many specialty areas.
About Pharmascience Inc.
Established in 1983 privately owned Pharmascience Inc. is the 3rd largest retail generic manufacturer, 10th largest pharmaceutical company in Canada, with a highly skilled workforce of 1,400 people. Pharmascience Inc. commercializes nearly 400 product families in 20 different dosage forms for over 2,000 products, including generic, branded prescription and over-the-counter consumer products. In Canada alone, more than 65 million prescriptions a year are filled with Pharmascience products. Additionally, Pharmascience has a significant international presence in 60 countries. Operationally, Pharmascience is fully integrated and controls all aspects of development and production, from manufacturing to commercialization.
SOURCE Pharmascience Inc.
For further information: Maria Angelini, Manager, Communications, Pharmascience Inc., (514) 340-7696, [email protected]